Amarantus will have into July 2018 to complete an up-listing of the Amarantus common stock to a national stock exchange (the "Uplist" and further extend the moratorium. Upon the Uplist, there will be a further 9-month (until April 2019) moratorium on liquidating the securities issued in the Tender Exchange, followed by a highly restricted 'leak-out' arrangement that will significantly limit the Tender Exchange holders' ability to convert.
https://www.amarantus.com/news/press-releases...ate-update

GC has been delivering and hasn't changed or updated the timeframe...  

1) Elto Pharma 
2) MANF Therapeutic 
3) Amarantus intends to assign these diagnostic assets to a new subsidiary that aligns with Amarantus' holding company business model. 

Aloha